Vitamin D levels and potential impact in systemic sclerosis

Clinical and Experimental Rheumatology

Volumn 29, Issue 6, 2011, Pages 1024-1031

  Vacca, Alessandra ^a   Mathieu, Alessandro ^b   Cormier, Catherine ^a   Kahan, André ^b   Allanore, Yannick ^b  

^a UNIVERSITY OF CAGLIARI   (Italy)

^b UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Autoimmune diseases; Disease activity; Hypovitaminosis D; Systemic sclerosis; Vitamin D

Indexed keywords

VITAMIN D; VITAMIN D DERIVATIVE;

ARTICLE; AUTOIMMUNE DISEASE; CALCIUM METABOLISM; DIET SUPPLEMENTATION; DIETARY INTAKE; DISABILITY; DISEASE ASSOCIATION; HUMAN; IMMUNOMODULATION; INSULIN DEPENDENT DIABETES MELLITUS; MULTIPLE SCLEROSIS; PREVALENCE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SKIN FIBROSIS; SUN EXPOSURE; SYSTEMIC LUPUS ERYTHEMATOSUS; SYSTEMIC SCLEROSIS; VITAMIN D DEFICIENCY;

ANIMALS; AUTOIMMUNE DISEASES; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; HUMANS; IMMUNOLOGIC FACTORS; SCLERODERMA, SYSTEMIC; VITAMIN D; VITAMIN D DEFICIENCY;

EID: 84857514918     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (105)

1. HOLICK MF: Vitamin D deficiency. N Engl J Med 2001;357; 266-81.
2. HOLICK MF, CHEN TC: Vitamin D deficiency: a wordwide problem with health consequences. Am J Clin Nutrition 2008;87:1080S-86S. (Pubitemid 351549267)
3. LIPS P: Vitamin D physiology. Progr Biophys Mol Biol 2006;92:4-8. (Pubitemid 43831956)
4. BOUILLON R: Vitamin D: from photosynthesis, metabolism, and action to clinical applications. In: DEGROOT U, JAMESON JL (Eds.) Endocrinology. Philadelphia: WB. Saunders 2001: p. 1009-28.
5. DELUCA HF: Overview of general physiologic features and functions of vitamin D. Am J Clin Nutr 2004;80:1689S-96S.
6. th ed. Washington DC: American Society for Bone and Mineral Research 2006: p. 129-37.
7. HOLICK MF: Sunlight and vitamin D for bone health and prevention of autoimmune diseases, cancers, and cardiovascular disease. Am J Clin Nutr 2004;80:1678S-88S.
8. NAGPAL S, NA S, RATHNACHALAM R: Noncalcemic actions of vitamin D receptor ligands. Endocr Rev 2005;26:662-87. (Pubitemid 41127276)
9. LI YC: Vitamin D regulation of the renin-angiotensin system. J Cell Biochem 2003;88:327-31. (Pubitemid 36119906)
10. MATHIEU C, ADORINI L: The coming of age Of 1, 25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trend Mol Med 2002;8:174-9. (Pubitemid 34297090)
11. CANTORNA MT, ZHU Y, FROICU M, WITTKE A: Vitamin D status, 1, 25-dihydroxy vitamin D3, and the immune system. Am J Clin Nutr 2004;80:1717S-20S.
12. BINKLEY N, NOVOTNY R, KRUEGER D et al.: Low vitamin D status despite abundant sun exposure. J Clin Endocrinol Metab 2007;92:2130-5. (Pubitemid 46997111)
13. CHAPUY MC, SCHOTT AM, GARNERO P, HANS D, DELMAS PD, MEUNIER J: Healthy elderly French women living at home have secondary hyperparathyroidism and high bone turnover in winter. J Clin Endocrinol Atab 1996;81:1129-33. (Pubitemid 26083981)
14. DAWSON-HUGHES B, HEANEY RP, HOLICK MF, LIPS P, MEUNIER PJ, VIETH R: Estimates of optimal vitamin D status. Osteoporos Int 2005;6:713-6. (Pubitemid 40933586)
15. MALABANAN A, VERONIKIS IE, HOLICK MF: Redefining vitamin D insufficiency. Lancet 1998;351:805-6. (Pubitemid 28112350)
16. HOLICK MF, SIRIS ES, BINKLEY N, BEARD MK, KHAN A, KATZER JT: Prevalence of vitamin D inadequacy among postmenopausal North American women receiving osteoporosis therapy. J Clin Endocrinol Metab 2005;90:3215-24. (Pubitemid 41014278)
17. THOMAS MK, LLOYD-JONES DH, THADHANI RI, SHAW AC, DERASKA DJ, KITCH BT: Hypovitaminosis D in medical inpatients. N Engl J Med 1998;338:777-83. (Pubitemid 28135983)
18. HEANEY RP, DOWELL MS, HALE CA, BENDICH A: Calcium absorption varies within the reference range for serum 25-hydroxyvitamin D. J Am CollNutr 2003;22:142-6. (Pubitemid 36417827)
19. CORMIER C, SOUBERBIELLE JC: New definition of optimal vitamin D status and redefining serum parathyroid hormone reference range. Rev Med Interne 2006;27:684-9. (Pubitemid 44322012)
20. HAUSSLER MR, WHITFIELD GK, HAUSSLER CA et al.: The nuclear vitamin D receptor: biological and molecular regulatory properties revealed. J Bone Miner Res 1998;13:325-49. (Pubitemid 28146215)
21. MONKAWA T, YOSHIDA T, HAYASHI M et al.: Identification of 25-hydroxyvitamin D3 1 alpha-hydroxylase gene expression in macrophages. Kidney Int 2000;58:559-68. (Pubitemid 30620005)
22. FRITSCHE J, MANDAL K, EHRNPERGER A et al.: Regulation of 25-hydroxyvitamin D3 1 alpha-hydroxylase and production of 1 alpha, 25-hydroxyvitamin D3 by human dendritic cells. Blood 2003;102:3314-6. (Pubitemid 37314772)
23. MATHIEU C, ADORINI L: The coming age of 1, 25-dihydroxyvitamin D3 analogs as immunomodulatory agents. Trends Mol Med 2002;8:174-9. (Pubitemid 34297090)
24. LEMIRE JM, ADAMS JS, SAKAI R, JORDAN SC: 1α, 25-dihydroxyvitamin D3 suppresses proliferation and immunoglobulin production by normal human peripheral blood mononuclear cells. J Invest 1984;74:657-61. (Pubitemid 14054016)
25. RIGBY WF, STACY T, FANGER MW: Inhibition of T lymphocyte mitogenesis by 1, 25-dihydroxyvitamin D3 (calcitriol). J Clin Invest 1984;74:1451-5. (Pubitemid 15200239)
26. BHALLA AK, AMENTO EP, KRANE SM: Differential effects of 1, 25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: inhibition of interleukin-2 and augmentation of interleukin-1 production. Cell Immunol 1986;98:311-22. (Pubitemid 16112035)
27. REICHEL H, KOEFFLER HP, TOBLER A, NORMAN AW: 1α, 25-dihydroxyvitamin D3 inhibits γ-interferon synthesis by normal human peripheral blood lymphocytes. Proc Natl Acad Sci USA 1987;84:3385-9. (Pubitemid 17085408)
28. RIGBY WF, YIRINEC B, OLDERSHAW RL, FANGER MW: Comparison of the effects of 1, 25-dihydroxyvitamin D3 on T lymphocyte subpopulations. Eur J Immunol 1987;17:563-6. (Pubitemid 17094157)
29. MEEHAN MA, KERMAN RH, LEMIRE JM: 1, 25-dihydroxyvitamin D3 enhances the generation of non specific suppressor cells while inhibiting the induction of cytotoxic cells in a human MLR. Cell Immunol 1992;140:400-9.
30. DANIEL C, SARTORY NA, ZAHN N, RADEKE HN, STEIN JM: Immune modulatory treatment of trinitrobenzene sulfonic acid colitis with calcitriol is associated with a change of a T helper (Th) 1/Th 17 to a Th2 And regulatory T cell profile. J Pharmacol Exp Ther 2008;324:23-33. (Pubitemid 350294165)
31. MOSSER DM, ZHANG X: Interleukin-10: new perspectives on an old cytokine. Immunol Rev 2008;226:205-18.
32. PENNA G, RONCARI A, AMUCHASTEGUI S et al.: Expression of the inhibitory receptor ILT3 on dendritic cells is dispensable for induction of CD4+Foxp3+ regulatory T cells by 1, 25-dihydroxyvitamin D3. Blood 2005;106:3490-7. (Pubitemid 41609185)
33. CHEN S, SIMS GP, CHEN XX, GU YY, CHEN S, LIPSKY PE: Modulatory effects of 1, 25-dihydroxyvitamin D3 on human B cell differentiation. J Immunol 2007;179:1634-47.
34. MULLER K, HEILMANN C, POULSEN LK, BARINGTON T, BENTZEN K: The role of monocytes and T cells in 1, 25-dihydroxyvitamin D3 mediated inhibition of B cell function in vitro. Immunopharmacology 1991;21:121-8.
35. SHIRAKAWA AK, NAGAKUBO D, HIESHIMA K, NAKAYAMA T, JIN Z, YOSHIE O: 1, 25-dihydroxyvitamin D3 induces CCR10 expression in terminally differentiating human B cells. J Immunol 2008;180:2786-95.
36. PENNA D, ADORINI L: AIpha, 25-dihydroxyvitamin D3 inhibits differentiation, maturation, activation, and survival of dendritic cells leading to impaired alloreactive T cell activation. J Immunol 2000;164:2405-11. (Pubitemid 30115468)
37. LEMIRE JM, ARCHER DC: 1, 25-dihydroxy vitamin D3 prevents the in vivo induction of murine experimental autoimmune encephalomyelitis. J Clin Invest 1991;87:1103-7.
38. CANTORNA MT, HAYES CE, DELUCA HF: 1, 25-dihydroxyvitamin D3 reversibly blocks the progression of relapsing encephalomyelitis, a model of multiple sclerosis. Proc Natl Acad Sci USA 1996;93:7861-4. (Pubitemid 26277129)
39. CANTORNA MT, HAYHES CE, DELUCA HF: 1, 25-dihydroxycholecalciferol inhibits the progression of arthritis in murine models of human arthritis. J Nutr 1998;128:68-72. (Pubitemid 28087178)
40. TETLOW LC, WOOLLEY DE: The effects of la, 25-dihydroxyvitamin D3 on matrix metalloprotease and prostaglandin E (2) production by cell of the rheumatoid lesion. Arthritis Res 1999;1:63-70. (Pubitemid 32223674)
41. LEMIRE JM, INCE A, TAKASHIMA M: 1, 25-Dihydroxy vitamin D3 attenuates the expression of experimental murine lupus of MRL/1 mice. Autoimmunity 1992;12:143-8.
42. DELUCA HF, CANTORNA MT: Vitamin D: its role and uses in immunology. FASEB J 2001;15:2579-85. (Pubitemid 33131084)
43. KOIZUMI T, NAKAO Y, MATSUI T et al.: Effects of corticosteroid and 1, 24R-dihydroxy-vitamin D3 administration on lymphoproliferation and autoimmune disease in MRL/MP-lpr/lpr mice, Int Arch Allergy Appl Immunol 1985;77:396-404. (Pubitemid 15238901)
44. VAISBERG MW, KANENO R, FRANCO MF, MENDES NF: Influence of cholecalciferol (vitamin D3) on the course of experimental systemic lupus erythematosus in Fl (NZ-BxW) mice. J Clin Lab Anal 2000;14:91-6. (Pubitemid 30250109)
45. CASTEELS K, WAER M, LAUREYS J, VALCKX D, DEPOVERE J, BOUILLON R: Prevention of autoimmune destruction of syngeneic islet grafts in spontaneously diabetic nonobese diabetic mice by a combination of a vitamin D3 analog and cyclosporine. Transplantation 1998;65:1225-32. (Pubitemid 28224342)
46. CANTORNA M, MAHON BD: Mounting evidence for vitamin D as an environmental factor affecting autoimmune disease prevalence. Exp Biol Med 2004;229:1136-42. (Pubitemid 39602256)
47. MUNGER KL, ZHANG SM, O'REILLY E et al.: Vitamin D intake and incidence of multiple sclerosis. Neurology 2004;62:60-5. (Pubitemid 38082871)
48. MERLINO LA, CURTIS J, MIKULS TR, CERHAN JR, CRISWELL LA, SAAG KG: Vitamin D intake is inversely associated with rheumatoid arthritis: results from the IOWA Women's Health Study. Arthritis Rheum 2004;50:72-7. (Pubitemid 38084289)
49. HYPPONEN E, LAARA E, JARVELIN M-R, VIRTANEN SM: Intake of vitamin D and risk of type 1 diabetes: a birth-cohort study. Lancet 2001;358:1500-3. (Pubitemid 33055701)
50. ALLANORE Y, AVOUAC J, KAHAN A: Systemic sclerosis: An update in 2008. Joint Bone Spine 2008;75:650-5.
51. ALLANORE Y, WIPFF J, KAHAN A, BOILEAU C: Genetic basis for systemic sclerosis. Joint Bone Spine 2007;74:577-83. (Pubitemid 350245624)
52. ARTAZA JN, NORRIS KC: Vitamin D reduces the expression of collagen and key profibrotic factors by inducing an antifibrotic phenotype in mesenchimal multipotent cells. J Endocrinol 2009;200:207-21.
53. SERUP J, HAGDRUP H: Vitamin D metabolites in generalized scleroderma. Evidence of a normal cutaneous and intestinal supply with vitamin D. Acta Derm Venereol 1985;65:343-5. (Pubitemid 15016220)
54. MATSUOKA LY, DANNENBERG MJ, WORTSMAN J, HOLLIS BW, JIMENEZ SA, VARGA J: Cutaneous vitamin D3 formation in progressive systemic sclerosis. J Rheumatol 1991;18:1196-8.
55. ORBACH H, ZANDMAN-GODDARD G, AMITAL H et al.: Novel biomarkers in autoimmune diseases. Prolactin, Ferritin, Vitamin D, and TPA levels in autoimmune diseases. Ann NY Acad Sci 2007;1109:385-400. (Pubitemid 47511381)
56. BRAUN-MOSCOVICI Y, FURST DE, MARKOVITS D et al.: Vitamin D, parathyroid hormone and acroosteolysis in systemic sclerosis. J Rheumatol 2008;35:2201-5.
57. CALZOLARI G, DATA V, CARIGNOLA R, ANGELI A: Hypovitaminosis D in sistemic sclerosis. J Rheumatol 2009;36:2844.
58. VACCA A, CORMIER C, PIRAS M, MATHIEU A, KAHAN A, ALLANORE Y: Vitamin D deficiency and insufficiency in 2 independent cohorts of patients with systemic sclerosis J Rheumatol 2009;36:1924-9.
59. CARAMASCHI P, DALLA GASSA A, RUZZENENTE O et al.: Very low levels of vitamin D in sistemic sclerosis patients. Clin Rheumatol 2010;29:1419-25.
60. RIOS FERNANDEZ R, FERNANDEZ ROLDAN C, CALLEJAS RUBIO JL et al.: Vitamin D deficiency in a cohort of patients with systemic scleroderma from the south of Spain. J Rheumatol 2010;37:1355.
61. BELLOLI L, UGHI N, MARASINI B: Vitamin D in systemic sclerosis. Clin Rheumatol 2011;30:145-6.
62. AVOUAC J, GUERINI H, WIPFF J et al.: Radiological hand involvement in systemic sclerosis. Ann Rheum Dis 2006;65:1088-92. (Pubitemid 44133273)
63. PATEL S, FARRAGHER T, BERRY J, BUNN D, SILMAN A, SYMMONS D: Association between serum vitamin D metabolite levels and disease activity in patients with early inflammatory polyarthritis. Arthritis Rheum 2007;56:2143-9. (Pubitemid 47173561)
64. KROGER H, PENTTILA IM, ALHAVA EM: Low serum vitamin D metabolites in women with rheumatoid arthritis. Scand J Rheumatol 1993;22:172-7. (Pubitemid 23233552)
65. OELZNER P, MILLER A, DESCHNER F et al.: Relationship between disease activity and serum levels of vitamin D metabolites and PTH in rheumatoid arthritis. Calcif Tissue Int 1998;62:193-8. (Pubitemid 28127929)
66. KAMEN DL, COOPER GS, BOUALI H et al.: Vitamin D deficiency in systemic lupus erythematosus. Autoimm Rev 2006;5:114-7. (Pubitemid 43129539)
67. HAQUE UJ, BARTLETT SJ: Relationships among vitamin D, disease activity, pain and disability in rheumatoid arthritis. Clin Exp Rheumatol 2010;28:745-7.
68. SHINJO SK, BONFÀ E, DE FALCO CAPARBO V et al.: Low bone mass in juvenile onset sclerosis: the possible role for 25-hydroxyvitamin D insufficiency. Rheumatol Int 2011;31:1075-80.
69. ELST EF, VAN SUIJLEKOM-SMIT LW, ORANJE AP: Treatment of linear scleroderma with oral 1, 25-dihydroxyvitamin D3 (calcitriol) in seven children. Pediatr Dermatol 1999;16:53-8. (Pubitemid 29102635)
70. HUMBERT PG, DUPOND JL, ROCHEFORT A et al.: Localized scleroderma-response to 1, 25-dihydroxyvitamin D3. Clin Exp Dermatol 1990;15:396-8.
71. DUPOND JL, HUMBERT P, ROCHEFORT A et al.: Traitement de la sclérodermic systemique et de la morphée par le 1, 25-dihydroxycholecalciferol. Rev Med Intern 1991;12: s26.
72. HUMBERT P, DUPOND JL, AGACHE P et al.: Treatment of scleroderma with oral 1, 25-dihydroxyvitamin D3: evaluation of skin involvement, using nonivasive techniques. Results of an open prospective trial. Acta Derm Venereol 1993;73:449-51. (Pubitemid 23351347)
73. HUMBERT P, DELAPORTE E, DUPOND JL et al.: Treatment of localized scleroderma with 1, 25-dihydroxyvitamin D3. Eur J Dermatol 1994;4:21-3.
74. HULSHOF MM, PAVEL S, BREEDVELD FC, DIJKMANS BAC, VERMEER BJ: Oral calcitriol as a new therapeutic modality for generalized morphea. Arch Dermatol 1994;130:1290-3. (Pubitemid 24313289)
75. HULSHOF MM, BOUWES BAVINCK JN, BERGMAN W et al.: Double-blind, placebocontrolled study of oral calcitriol for the treatment of localized and systemic scleroderma. J Acad Dermatol 2000;43:1017-23.
76. CLEMENS TL, ADAMS JS, HOURIUCHI N et al.: Interaction of 1, 25-dihydroxyvitamin D3 with keratinocytes and fibroblast from skin of normal subjects and a subject with vitamin D dependent rickets, type II: a model for study of the mode of action of 1, 25-dihydroxyvitamin D3. J Clin Endocrinol Me tab 1983;56:824-30. (Pubitemid 13165453)
77. TSOUKAS CD, PROVVEDINI DM, MANOLAGAS SC: 1, 25-dihydroxyvitamin D3: a novel immunoregolatory hormone. Science 1984;224:1438-40.
78. BOELSMA E, PAVEL S, PONEC M: Effects of calcitriol on fibroblast derived from skin of scleroderma patients. Dermatology 1995;191:226-33.
79. BOTTOMLY WW, JUTLEY J, WOOD EJ, GOODFIELD MDJ: The effect of calcipotriol on lesional fibroblasts from patients with active morphoea. Acta Derm Venereol 1999;75:364-66.
80. CUNNINGHAM BB, LANDELLS ID, LANGMAN C, SAILER DE, PALLER A: Topical calcipotriene for morphea/linear scleroderma. J Am Acad Dermatol 1998;39:211-5. (Pubitemid 28367331)
81. CAGNONI ML, GHERSETICH I, LOTTI T, PIERLEONI M, LANDI G: Treatment of psoriasis vulgaris with topical calcitriol. Acta Derm Venereol 1994;186:55-7.
82. O'REAGAN S, CHESNEY RW, HAMSTRA A et al.: Reduced serum 1, 25 (OH) 2 vitamin D3 levels in prednisone-treated adolescent with systemic lupus erythematosus. Acta Paediatr Scand 1979;68:109-11. (Pubitemid 9018907)
83. BULTNIK IE, LEMS WF, KOSTENSE PJ et al.: Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 2005;52:2044-50. (Pubitemid 40994328)
84. TEICHMANN J, STEPHAN E, DISCHER T et al.: Bone metabolism and bone mineral density of systemic lupus erythematosus at the time of diagnosis. Rheumatol Int 1999;18:137-40.
85. MULLER K, KRIEGBAUM NJ, BASLUND B et al.: Vitamin D3 metabolism in patients with rheumatic diseases: low serum levels of 25-hydroxyvitamin D in patients with systemic lupus erythematosus. Clin Rheumatol 1995;14:397-400.
86. HUISMAN AM, WHITE KP, ALGRA A et al.: Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 2001;28:2535-9. (Pubitemid 33031987)
87. CUTOLO M, OTSA K: Vitamin D, immunity and lupus. Lupus 2008;17:6-10. (Pubitemid 351487012)
88. RUIZ-IRASTORZA G, EGURBIDE MV, OLIVARES N et al.: Vitamin D deficiency in sistemic lupus erythematosus: prevalence, predictors and clinical consequences. Rheumatol 2008;47:920-3. (Pubitemid 351796385)
89. RUIZ-IRASTORZA G, GORDO S, OLIVARES N et al.: Changes in vitamin D levels in patients with systemic lupus erythematosus: effects on fatigue, disease activity and damage. Arthritis Care Res (Hoboken) 2010;62:1160-65.
90. CARVALHO JF, BLANK M, KISS E et al.: Anti-vitamin D, vitamin D in SLE: preliminary results. Ann NY Acad Sci 2007;1109:550-7. (Pubitemid 47511398)
91. ZOLD E, SZODORA Y, GAAL J et al.: Vitamin D deficiency in Undifferentiated Connective Tissue Disease. Arthritis Res Ther 2008;10:R123.
92. HAJAS A, SANDOR J, CSATHY L et al.: Vitamin D insufficiency in a large MCTD population. Autoimmun Rev 2011;10:317-24.
93. HAMZAOUI K, BEN DHIFALLAH I, KARRAY E et al.: Vitamin D modulates peripheral immunity in patients with Behçet disease. Clin Exp Rheumatol 2010;28:S50-S57.
94. LEVENTIS P, PATEL S: Clinical aspects of vitamin D in the management of rheumatoid arthritis. Rheumatology 2008;47:1617-21.
95. CHEN TC, CHIMEH F, LU Z et al.: Factors that influence the cutaneous synthesis and dietary sources of vitamin D. Arch Biochem Biophys 2007;460:213-7. (Pubitemid 46613793)
96. TAKAHASHI T, MORIKAWA K: Vitamin D receptor agonists: opportunities and challenges in drug discovery. Curr Top Med Chem 2006;6:1303-16. (Pubitemid 44110919)
97. FESKANICH D, MA J, FUCHS CS: Plasma vitamin D metabolites and risk of colorectal cancer in women. Cancer Epidemiol Biomarkers Prev 2004;13:1502-8. (Pubitemid 39202318)
98. GIOVANNUCCI E, LIU Y, WILLETT WC: Cancer incidence and mortality and vitamin D in black and wite male health professionals. Cancer Epidemiol Biomarkers Prev 2006;15:2467-72. (Pubitemid 46048306)
99. FORMAN JP, GIOVANNUCCI E, HOLMES MD et al.: Plasma 25-Hydroxyvitamin D levels and the risk of incident hypertension. Hypertension 2007;49:1063-9. (Pubitemid 351664326)
100. GIOVANNUCCI E, LIU Y, HOLLIS BW, RIMM EB: 25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med 2008;168:1174-80. (Pubitemid 351831400)
101. DOBNIG H, PILZ S, SCHARNAGL H et al.: Independent association of low serum 25-hydroxyvitamin D and 1, 25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med 2008;168:1340-9. (Pubitemid 351930842)
102. AUTIER P, GANDINI S: Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med 2007;167:1730-7. (Pubitemid 47403059)
103. LIU PT, STENGER S, LI H et al.: Toll-Like receptor triggering of a vitamin D-mediated human antimicrobial response. Science 2006;311:1770-3.
104. CHIU KC, CHU A, GO VL, SAAD MF: Hypovitaminosis D is associated with insulin resistance and beta cell dysfunction. Am J Clin Nutr 2004;79:820-5. (Pubitemid 41103882)
105. SOUBERBIELLE JC, BODY JJ, LAPPE JM et al.: Vitamin D and musculoskeletal health, cardiovascular disease, autoimmunity and cancer: recommendations for clinical practice. Autoimmun Rev 2010;9:709-15.